Search

Garvagliptin

Garvagliptin has a monoisotopic molecular weight of 399.14 Da. … Garvagliptin is a small molecule drug. The usage of the INN stem '-gliptin' in the name indicates that Garvagliptin is a dipeptidyl aminopeptidase-IV inhibitor.

Tozasertib

Tozasertib has a monoisotopic molecular weight of 464.21 Da. … Tozasertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Tozasertib is a serine/threonine kinase inhibitor.

Zelicapavir

Zelicapavir has a monoisotopic molecular weight of 549.17 Da. … Zelicapavir is a small molecule drug. The usage of the INN stem '-capavir' in the name indicates that Zelicapavir is a viral capsid and nucleocapsid inhibitor.

Briakinumab

Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.

Tozorakimab

Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. … moderate-to-severe asthma), NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in

Cilazaprilat

QR-333

QR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder … QR-333 has been investigated as a treatment for diabetic peripheral neuropathy.

PX-12

tumor growth in animal models. … Since high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced

Viper antivenom

ANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation

EW-A-401

This specific transcription factor has been shown in animal studies to increase expression of the VEGF-A gene, and to promote the growth of new blood vessels. … EW-A-401 is a circle of genetic material (plasmid DNA) that instructs the body to produce a genetically-engineered transcription factor, a protein that regulates expression of genes.